NYSE:TLK

PT Telkom Indonesia (Persero) Tbk (NYSE: TLK) Faces Earnings Scrutiny and Valuation Challenges

Font: Financial Modeling Prep  • May 19, 2026

Market Chart
  • PT Telkom Indonesia (Persero) Tbk (NYSE: TLK) is set to release its quarterly earnings, with analysts forecasting an EPS of $0.42 and revenue of $2.3 billion.
  • The company's recent performance includes a 24.7% EPS decline in fiscal year 2025, and its fiscal year 2026 revenue growth outlook is below consensus.
  • Despite a recent 4.5% share price increase and an estimated GF Value of $19.53 suggesting undervaluation, the stock was recently downgraded from "Buy" to "Hold" by Seeking Alpha.

PT Telkom Indonesia (Persero) Tbk (NYSE: TLK) is a major telecommunications company based in Indonesia. The company provides a wide range of network and telecommunication services. As a publicly traded entity on the New York Stock Exchange, it regularly files reports, including its recent 2025 annual report on Form 20-F.

Investors are watching TLK as it prepares to release its quarterly earnings report on May 20, 2026. Wall Street analysts are forecasting an earnings per share (EPS) of $0.42. An EPS figure shows how much profit the company makes for each share of its stock.

For the upcoming quarter, revenue is estimated to be around $2.3 billion. This forecast follows a period of weaker performance, as the company's fiscal year 2025 results missed expectations with an EPS decline of 24.7%. As highlighted by Seeking Alpha, the outlook for fiscal year 2026 revenue growth is also below consensus.

Ahead of the report, TLK shares rose 4.5% to close at $17.32 on May 18, 2026. An analysis by GuruFocus considers the stock undervalued, with its current price below the estimated GF Value of $19.53. The stock has shown volatility, trading within a 52-week range of $15.63 to $23.52.

The company's financial health shows a Debt-to-Equity ratio of 0.57, indicating it has more equity than debt financing its assets. Despite this, a Seeking Alpha report recently downgraded the stock's rating from "Buy" to "Hold," citing poor financial prospects but also noting strong progress in corporate restructuring.

Market Overview
TZA
Direxion Daily Small Cap Bear 3X ETF
$4.83
-7.29%
SLXN
Silexion Therapeutics Ltd.
$0.53
96.95%
HAO
Haoxi Health Technology Limited
$0.01
0.71%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$8.54
-14.00%
MEHA
Functional Brands, Inc. Common Stock
$0.09
21.95%
JUNS
Jupiter Neurosciences, Inc.
$0.21
-35.94%
PHGE
BiomX Inc.
$0.60
59.60%
WOK
WORK Medical Technology Group Ltd.
$0.19
-19.57%
HCWB
HCW Biologics Inc.
$2.43
129.25%
GDC
GD Culture Group Limited
$0.12
-17.44%